DOPTELET 20mg film coated tablets

  • Name:

    DOPTELET 20mg film coated tablets

  • Company:
    info
  • Active Ingredients:

    Avatrombopag

  • Legal Category:

    Product subject to restricted prescription (C)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 26/01/21

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 26/1/2021
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Swedish Orphan Biovitrum Ltd

Swedish Orphan Biovitrum Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name ALPROLIX powder and solvent for solution for injection Active Ingredients Eftrenonacog Alfa
Medicine Name DOPTELET 20mg film coated tablets Active Ingredients Avatrombopag
Medicine Name ELOCTA powder and solvent for solution for injection Active Ingredients efmoroctocog alfa
Medicine Name Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe Active Ingredients Anakinra
Medicine Name Orfadin 2mg, 5mg, 10mg and 20mg Capsules Active Ingredients Nitisinone
Medicine Name Orfadin 4mg/ml Oral Suspension Active Ingredients Nitisinone
1 - 0 of 6 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 26 January 2021 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)

Legal category: Product subject to restricted prescription (C)

Updated on 26 January 2021 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product looks like and pack contents

Updated on 14 October 2020 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to restricted prescription (C)

Updated on 14 October 2020 PIL

Reasons for updating

  • New PIL for new product